Protein extraction and western blot analysis
The tissues were homogenized after adding 1ml PRO-PREP TM (iNtRon, Gyeonggi, Korea) to 20mg tissue and was kept on ice for about 30 minutes for cytolysis and centrifuged at 12,000 rpm and 4°C for 15 minutes to generate supernatant. Protein concentration was measured using Bradford assay (Molecular devices max190). For Western blot, 30-60 µg protein per well was loaded on 10% sodium dodecylsulfate-plyacrylamide gel for electrophoresis (SDS-PAGE). The proteins were transferred on PVDF membrane (Amersham, London, UK). The membrane was incubated with primary antibody for overnight at 4°C. The membrane was later incubated with secondary antibody and protein expression was confirmed using ECL (GenDEPOT, Seoul, Korea 
Cell culture
Human hepatoma cell line (HepG2) were cultured in Dulbecco's modified Eagle's medium (Gibco, NY, USA) containing fetal bovine serum (Gibco, NY, USA) and 100 mg/mL streptomycin (Gibco, NY, USA) using 5% CO 2 incubator at 37°C.
Assessment of cell viability (MTT Assay)
1.5 × 10 5 cells were seeded on a 96 well plate. After 24 hour 400 µM PA and 800 µM OA was added to establish vitro NAFLD model. After 2 hr G-CSF (0.1-100 ng/ml) was added to the wells. After 24 and 48 hours, 20 µl Cell Titer 96 Aqueous One Solution (Promega, Madison, WI, USA) was added to determine cell viability. After 4 hr, 96-well plate was read using Microplate Reader (Emax microplate reader, Molecular Devices, CA, USA) at 490 nm.
Assessment of oxidative stress (ROS Assay)
1.5 × 10 5 cells were seeded on 96 well plate. After 24 hour 400 µM PA and 800 µM OA was added to establish vitro NAFLD model. After 2 hour, 100ng/ml G-CSF was added. After 24 hour 5 µM DCF-DA (Sigma, MO, USA) was added and reactive Oxygen Species (ROS) was measured using Victor3 (Perkin Elmer, MD, USA).
Triglyceride measurements (Nile red Staining)
In vitro NAFLD model was established as previously mentioned. After 20 mins the cells were washed using PBS, 10 µg/ml Nile red (Sigma, CA, USA) was added and plate was read using Microplate reader (iMark, Bio-Rad, CA, USA). 0.010 C, control; N, high fat induced fatty liver disease; G1, G-CSF treatment once weekly from 8th to 12th week; G2, G-CSF treatment daily for 5 consecutive days in 9th week; G3, G-CSF treatment twice weekly from 9th to 12th week. 0.538 C, control; N, high fat induced fatty liver disease; G1, G-CSF treatment once weekly from 8th to 12th week; G2, G-CSF treatment daily for 5 consecutive days in 9th week; G3, G-CSF treatment twice weekly from 9th to 12th week. 
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